PATENT CLAIM ANALYSIS

Application Number: 15918136
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["424", "133100"]

Abstract:
This invention relates to methods employing IL-1 beta-ligand/IL-1 receptor disrupting compounds, such as IL-1 beta antibodies or IL-1 receptor antibodies, in the treatment and/or prevention of auto-inflammatory syndromes in mammals, particularly humans.

Claim (Index 5):
The method of  claim 4 , wherein the IL-1beta antibody is a human antibody.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 90.0
- Lexical Diversity: 1.24138
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14810556', '12090490', '13283165', '13171631', '15359784']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8011718292447676
- 35 USC 102 Novelty (BERT): 0.6008535786760696
- Combined Prediction Score: 0.7811400041878978
- Mean Citation Score: 462.73160400000006
- Max Citation Score: 536.51483
- Similarity Product: 477.15118932824913

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test